Biotech China 2014

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. CRF1 receptors within the rat basolateral amygdala mediate a subset of anxiety behaviors induced by central CRF infusions Campbell BM, Morrison JL, Walker EL, Merchant KM. NA January, 2013
2. Is there an opportunity to refine disease taxonomy based on biomarkers for psychiatric Disorders? Wellcome Trust Conference on Biomarkers for Brain Disorders: Challenges and Opportunities, Cambridge, England January, 2013
3. Improving Clinical Success Through Optimal Target Validation 7th Annual Drug Discovery for Neurodegeneration Conference, San Francisco, USA January, 2013
4. Derisking Targets for Drug Discovery: a-synuclein as a target for Parkinson’s Disease Indiana University Purdue University at Indianapolis, Indianapolis, USA January, 2013
5. Derisking Targets for Disease Modifying Therapies of Parkinson’s Disease Rush University Medical Center, Chicago, USA January, 2013
6. Parkinson’s Disease Therapeutics Chair, New York Academy of Sciences and Michael J Fox Foundation Conference January, 2012
7. How does translational science improve the quality of drug candidates and provide benefit for individual patients? Annual Congress of International Drug Discovery Science and Technology, Nanjing, China January, 2012
8. Development of Biomarkers of Cocaine Abuse CPDD Workshop, Arizona, USA January, 2012
9. LRRK2: Can we target it for therapeutic discovery? Lifetech Parkinson’s Symposium, Indianapolis, USA January, 2012
10. Are We at a Turning Point in Psychiatric Genetics? Annual meeting of American College of Neuropsychopharmacology, Florida, USA January, 2012
11. Target Validation: A Key Factor for Future Success in Pharma R&D. Workshop Chair at Next Generation Pharma Drug Discovery Summit, Bremen, Germany January, 2011
12. A Tale of Two Targets (LRRK2 and a-synuclein): How Imminent is a Disease-Modifying Therapy for Parkinson’s Disease? Purdue University, USA January, 2011
13. Animal Models of PD: Are they Translational Enough to Aid Drug Discovery? NY Academy of Sciences and Michael J Fox Foundation Conference on Parkinson’s Disease Therapeutics January, 2010
14. Biomarkers and Biomarker Technologies for Glutamatergic Therapeutics: Progress, Opportunities and Challenges Institute of Medicine Workshop, Washington, D.C, USA January, 2010
15. Translational Science Approaches - from Target Discovery Through Patient Tailoring. The Annual Global Drug Discovery and Development Innovation Leaders Summit, Orlando, USA January, 2010
16. Functional Genomics and Systems Biology Approaches to Discover Novel Targets for Parkinson’s Disease Boston University, USA January, 2009
17. Opportunities and Challenges for Target Discovery and Validation for Parkinson's Disease Medical University of South Carolina Grand Rounds, USA January, 2009
18. LRRK2 in Parkinson’s disease: A target for neuroprotection? Annual Meeting of American Society for Neurochemistry, USA January, 2008
19. LRRK2: Hottest Target for Parkinson's Disease? University of Pittsburgh, USA January, 2008
20. Gene Expression Profiling to Discover Biomarkers of Parkinson’s disease, Annual Meeting of Parkinson’s Study Group, USA January, 2008
21. Preparing for the Challenges and Opportunities in Drug Discovery and Development Research University of Utah, USA January, 2007
22. Opportunities and Challenges for New Target Discovery for Disease Modifying Therapies for Parkinson’s Disease Cornell University School of Medicine, USA January, 2007
23. Genetics of Parkinson’s disease: Opportunities for New Target and Drug Discovery for Disease Modifying Therapy GRECC- Seattle VA Medical Center and University of Washington, USA January, 2006
24. Cellular pathways associated with activation of AMPA receptors by allosteric modulators: relevance to pleiotropic neuropharmacology of AMPA potentiators V. Lakics, JW Ryder, TR Stewart, J Shou, FG Boess, KM Merchant Society for Neuroscience January, 2006
25. Metabolic Profiling of Cerebral Spinal fluid Utilizing Gas Chromatography Mass Spectrometry with Negative Chemical Ion Detection. JA Eckstein, GM Londino, KM Merchant, BL Ackermann. American Society for Mass Spectrometry Meeting January, 2006
26. Proteasomal Inhibition Increases alpha-Synuclein Levels In An Amyloid-beta-Dependent Manner. Mark Frasier, C DeLong, K Bales, KM Merchant 10th International Congress on Alzheimer’s Disease and Related Disorders January, 2006
27. Biochemical and histological studies of leucine rich repeat kinase 2 (LRRK2). KM Merchant, M Frasier, J Tzaferis, L Li, J Ryder, C DeLong, K Bales, A Kingston 10th International Congress on Alzheimer’s Disease and Related Disorders January, 2006
28. Activation of AMPA Channels by the Allosteric Modulators, LY404187 and LY503430, Increases Cerebellar cGMP Content in the Mouse JW Ryder, D Czilli, J Falcone, KA Svensson, KM Merchant Society for Neuroscience January, 2005
29. Improving the probability of technical success for development of disease modifying therapies Neurodegenerative Drug Development Forum, London, England January, 2005
30. Neuroendocrine, behavioral and synaptic protein changes in rats subjected to a chronic, variable stress paradigm for two weeks: a model for discovering drugs for stress-related disorders? Sahr RN, E Crile, R Crile, J Hart, M Morin, D Gehlert, D McKinzie, M Bergeron, KM Merchant American College of Neuropsychopharmacology, Neuropsychopharmacology, 29:S156, Abstract 89 January, 2004
31. Further Evidence of Deficits in Hippocampal Synaptic Viability in Young, Pre-plaque PDAPP Mice Sahr RN, Ryder JW, Koger D, Bales KR, Merchant KM International Congress on Alzheimer’s Disease and related Disorders, Abstract P3-324 January, 2004
32. Role of the CRF1 Receptor in Corticotropin-Releasing Factor Induced Behavioral, Neuroendocrine and Genomic Responses Walker EL, Morrison JL, Campbell BM, Merchant KM Abstract No. 538..8, Society for Neuroscience January, 2003
33. Bridging the gap between pre-clinical and clinical testing of the amyloid hypothesis IBC conference on Drug Discovery and Development for Neurodegenerative Diseases, Copenhagen, Denmark. January, 2003
34. Reduced A levels in Tg2576 Brain, CSF and Plasma by potent -secretase inhibitors, but not by NSAIDs Lanz TA, Wu H, Landrum CS, Ellerbrock BR, Nye JS, Merchant KM. Abstract No. 729.1, Society for Neuroscience January, 2003
35. Early Onset of Hippocampal-specific Decreases in Dendritic Spine Density in Transgenic Mice Over-expressing Human Mutant APP. Lanz, T.A.; K.M. Merchant. Abst. 8th International Conference on Alzheimer’s Disease and Related Disorders, 23: 1776 January, 2002
36. Presenilin enhancers PEN-1 and PEN-2 and their roles in A-beta productions. Li, J-h, R Myers, R. Shuang, D Carter, D McKinely, R Hiebsch, B. Ellerbrock, T. Fleck, C. Himes, C. Ruble, M. Carozza, R.F. Drong, A. Pauley, K. Schellin, L. Seaver, J. Slightom, P. Ruppel, G. Donoho, G.J. Fici, E.L. Walker, K.M. Merchant, C. Mao, D. Stephenson, D. Elrod, I. Reardon, K-C Chen, A. Karnovsky, D. Evans, S. Sharma, G.J. Cavey, W.R. Mathews, J. Bleasdale, M. Gurney, I. Kola, J.F. Nye Abst. 8th International Conference on Alzheimer’s Disease and Related Disorders, 23: 777 January, 2002
37. Anxiogenic-like effects of serotonin 2c receptor stimulation within the amygdala: a comparison between the basolateral and central nuclei Campbell BM, Merchant KM NYAS: Amygdala in Brain Function, Galveston, TX January, 2002
38. The -secretase inhibitor, DAPT, differentially reduced A levels in vivo in brain, plasma, and CSF in young and old Tg2576 mice Lanz TA, Himes CS, Merchant KM. Abstract No. 483.6. Society for Neuroscience January, 2002
39. Stress-induced Vulnerability of Hippocampal Neurons: Biochemical and Morphometric Alterations and Their Functional Implications for CNS Disorders Kalamazoo College, USA January, 2002
40. Neuroplasticity and schizophrenia pathophysiology: Effects of classical and novel antipsychotics University of Cincinnati, USA January, 2000
41. Preclinical Models of psychosis and depression: Neuroplastic responses and drug effects University of Kentucky, USA January, 1999
42. Preclnical models of anxiety disorders NCDEU Annual Meeting, USA January, 1999
43. Blockade of the expression of behavioral sensitization to amphetamine by the selective dopamine D4 receptor antagonist, PNU-101387G Needham L.M., Merchant K.M Poster Abstract, International Conference on Schizophrenia Research January, 1997
44. Amphetamine Sensitization: Role of Dopamine D4 Receptor in Behavioral and Molecular Effects St. Louis University, USA January, 1997
45. Dopamine D4 blockade prevents the behavioral and biochemical changes associated with amphetamine sensitization: comparison to haloperidol and clozapine. Feldpausch, D.L., Meng Z-h, Needham, L.M., Stone, L.M., Svensson K.A., Merchant, K.M Poster Abstract, International Conference on Schizophrenia Research January, 1997
46. Amphetamine-induced behavioral sensitization and associated changes in c-fos/neurotensin mRNA expression in rats: effects of clozapine, haloperidol and PNU-101387G Meng, Z.-h, Feldpausch D.L., Merchant K.M., Abst. Soc. Neurosci., 23: 522 January, 1997
47. Dopamine D4 receptor antagonist blocks the expression of amphetamine sensitization by enhancing dynorphin neurotransmission Garimella, B, H. Wu, C.S. Fitch, K. Essani, K.M. Merchant Abst. Soc. Neurosci., 23: 2240 January, 1997
48. Role of dopamine D4 receptor in psychostimulant sensitization Oregon health Sciences University, USA. January, 1997
49. Dopamine D4-selective antagonist, U-101387G, blocks amphetamine-sensitization in rats: behavioral and biochemical changes Feldpausch, D.L., L.M. Needham, Z.H. Meng, M.P. Stone, K.A. Svensson, K.M. Merchant Abst. Soc. Neuroscience, 22:1773, 1996 January, 1996
50. Alterations in Regional Gene expression and Effects on Development of Psychostimulant Sensitization By Dopamine D2-subtype Selective Antagonists National Institute for Mental Health, USA January, 1996
51. Role of D2, D3 and D4 Dopamine Receptors In Regional Alterations In Gene Expression And Psychostimulant Sensitization University of Colorado, USA January, 1996
52. Alterations in GAD65 mRNA levels in the basal ganglia after chronic dopamine agonists in 6-OHDA-lesioned rats Merchant, K.M., L.M. Needham, N.F. Nichols, D.L. Feldpausch Abst. Soc. Neuroscience, 22:1772, 1996 January, 1996
53. Progressively greater blockade of D2 dopamine receptors may interfere with c-fos induction in rat prefrontal cortex by clozapine Meng, Z.H., L.M. Needham, K.M. Merchant Abst. Soc. Neuroscience, 22:1773 January, 1996
54. Effects of a selective D4 dopamine antagonist on amphetamine-induced c-fos and NGFI-A mRNA expression Garimella, B., A. Jazayeri, C.M. Spangler, K. Essani, K.M. Merchant Abst. Soc. Neuroscience, 22:1773, 1996 January, 1996
55. Dopamine release is increased in the accumbal shell of amphetamine-sensitized rats: blockade by the D4-selective antagonist, U-101387G Merchant, K.M. and B.K. Yamamoto Abst. Soc. Neuroscience, 22:1773 January, 1996
56. Alterations in c-fos, NGFI-A and neurotensin mRNA expression in rats sensitized to amphetamine D.L. Evans, L.M. Figur, M.P. Stone, K.A. Svensson, K.M. Merchant Abst. Soc. Neurosci., 21: 1469 January, 1995
57. Differential distribution of GABA-A receptor subunits 1, 2, 3, 5 and 2+3 immunoreactivity in the infralimbic region of the rat prefrontal cortex; relevance to novel antipsychotic drug treatment Dunn, E., J-M Fritschy, D.B. Carter, K.M. Merchant Abst. Soc. Neurosci., 21: 2046 January, 1995
58. Immediate Early Gene Expression: Markers of Factors Involved in Pathophysiology and Pharmacotherapy of psychotic Disorders. Department of Pharmacology, Michigan State University, USA January, 1995
59. From Project Conception to the Clinic: U101387, a Dopamine D4-selective Compound for Treatment of Schizophrenia Department of Pharmacology, University of Colorado, USA January, 1995
60. A point mutation in a Ser-Pro change in the third extracellular domain of the human D3 receptor abolishes high affinity D3 binding P.G. Zaworski, D.L. Evans, L. Figur, E. Adams, J. Slightom, K. Merchant and G.S. Gill Abst. Soc. Neurosci., 21: 624 January, 1995
61. c-fos and neurotensin mRNA induction in the rat medial prefrontal cortex by atypical antipsychotics: Role of D3 receptors L.M. Figur, D.L. Evans, K.M. Merchant Abst. Soc. Neurosci., 21: 854 January, 1995
62. Role of cytokines in neurodevelopment: Relevance to developmental model of schizophrenia B. Garimella, A. Jazayeri, C.S. Spangler, K. Essani, K.M. Merchant Abst. Soc. Neurosci., 21: 1041 January, 1995
63. Cellular and Molecular Markers of Antipsychotic Drug Effects: Departments of Psychiatry and Pharmacology KEM Medical College, Bombay, India January, 1995
64. Atypical antipsychotic drugs and the prefrontal cortex: clues to therapy and pathophysiology of schizophrenia G. Jaskiw, K.M. Merchant, B. L. Yamamoto, B. Lipska and D. Pickar workshop at 27th Annual Winter Conference on Brain Research January, 1994
65. Cellular and Molecular Effects of Antipsychotic Drugs: Loci of Therapeutic versus Adverse Motor Effects Queen's University, Ontario, Canada January, 1994
66. Uht, Immediate-early gene-steroid hormone receptor interactions: Implications for molecular and behavioral neurobiology Dorsa, D.M., R.J. Handa, K.M. Merchant, P.M. Wise, and R workshop at 27th Annual Winter Conference on Brain Research January, 1994
67. Cellular Mechanisms Underlying the Pathophysiology and Pharmacotherapy of Schizophrenia Department of Biological Sciences, Western Michigan University, USA January, 1994
68. Antipsychotic Drug-induced Gene Regulation Department of Pharmacology, University of Ottawa, Ottawa, Ontario, Canada January, 1994
69. Age-related alterations in central dopaminergic neurotransmission, Geriatric Research Education and Clinical Center Research Seminar, Seattle VA Medical Center, USA January, 1993
70. Cellular and molecular substrates of antipsychotic drugs University of Pennsylvania, USA January, 1993
71. Alteration in neurotensin and c-fos gene expression by antipsychotic drugs Pfizer Central Research, USA January, 1993
72. Correlation between tolerance in neurotensin gene expression and cataleptic response in rats following continuous haloperidol treatment Merchant K. M. and D. J. Dobie Abst. Soc. Neurosci, 19: 1364 January, 1993
73. Irreversible monoaminergic receptor antagonism partially blocks the striatal neurotensin mRNA response to haloperidol in young but not senescent rats Dobie, D.J., M. R. Adams, K. M. Merchant, E. R. Peskind and D. M Dorsa Abst. Soc. Neurosci., 19: 1065 January, 1993
74. Examination of the role of the GABAergic systems in regulation of striatal neurotensin gene expression in the rat Decker, K.P., P. Roy-Byrne and K. M. Merchant Abst. Soc. Neurosci., 19: 1367 January, 1993
75. Region-specific effects of antipsychotic drugs on rat neostriatal neurotensin gene expression Merchant, K.M., D.J. Dobie and D.M. Dorsa Winter Neuropeptide Conference January, 1993
76. Differential Induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics in striatal regions of the rat brain Merchant K.M. and D.M. Dorsa Abst., International Congress on Schizophrenia Research, 1993 (Travel Awardee). January, 1993
77. Basal Ganglia Gene Expression and Movement Disorders Harborview Medical Center, Seattle, USA January, 1992
78. c-fos mRNA response to acute haloperidol is blunted in the striatum of aged rats Dobie, D.J., K.M. Merchant and D.M. Dorsa Abst. Soc. Neurosci, 18: 1434, 1992 January, 1992
79. Haloperidol-induced neurotensin gene expression is reduced by chronic treatment Merchant, K.M., D.J. Dobie and D.M. Dorsa Abst. Soc. Neurosci, 18: 984 January, 1992
80. Sexual dimorphism in estrogen-induced regulation of proneurotensin mRNA in the preoptic region of rat brain Merchant K.M., M.A. Miller and D.M. Dorsa Abstracts Endocrine Soc., 1991 January, 1991
81. Differential effects of typical and atypical neuroleptics on neurotensin gene transcription Merchant K.M., P.R. Dobner and D.M. Dorsa Abst. Soc. Neurosci, 17:548, 1991 January, 1991
82. Age-related decreases in dopamine D2 receptor mRNA expression in rat neostriatum Dorsa, D.M., K.M. Merchant, D.J. Dobie and M. Hamblin Abst. Soc. Neurosci, 17:816, 1991 January, 1991
83. Cellular and Molecular Mechanisms Underlying the Effects of Antipsychotic Drugs University Department of Chemical Technology, Bombay, India. January, 1991
84. Haloperidol rapidly increases the NT mRNA levels in the neostriatum of the rat Merchant, K.M., M.A. Miller, E.A. Ashleigh and D.M. Dorsa Abst. Soc. Neurosci., 16:1170, 1990 January, 1990
85. Role of NMDA receptors in dopamine D1 but not D2 mediated changes in striatal neurotensin Singh, N.A., K.M. Merchant, L.G. Bush, J.W. Gibb and G.R. Hanson Abst. Soc. Neurosci., 16:679 January, 1990
86. Gonadal steroid regulation of expression of the vasopressin gene in extrahypothalamic vasopressin neurons: Implications for sexually dimorphic behavior Dorsa, D.M., M.A. Miller, J.H. Urban, D.J. Dobie, K.M. Merchant, J. Bicknell and M.D. Brot 2nd International Congress of Neuroendocrinology Abstracts, S2.1, 1990 January, 1990
87. Nemeroff, Haloperidol and sigma receptor ligand BMY 14802 increase regional brain neurotensin and proneurotensin mRNA concentrations Levant, B., K.M. Merchant, D.M. Dorsa and C.B International Congress on Schizophrenia Research, 1990 January, 1990
88. Tonic regulation of the neurotensin systems by basally released dopamine in the basal ganglia Merchant, K.M., J.W. Gibb and G.R. Hanson Abst. Soc. Neurosci.,15:582, 1989 January, 1989
89. Dopaminergic regulation of neuropeptide Y systems Midgley, L., K.M. Merchant, J.W. Gibb and G.R. Hanson Abst. Soc. Neurosci., 15:581, 1989 January, 1989
90. Role of glutamate in dopamine-mediated neurotensin changes Singh, N.A., K.M. Merchant, J.W. Gibb and G.R. Hanson Abst. Soc. Neurosci., 15:582, 1989 January, 1989
91. Effects of fenfluramine, norfenfluramine and methamphetamine on extrapyramidal peptides Singh, N.A., K.M. Merchant, J.W. Gibb and G.R. Hanson ASPET, 219, 1989. January, 1989
92. Characterization of methamphetamine effects on striatal-nigral dynorphin system Hanson, G. R., L. Bush, K.M. Merchant and J. W. Gibb FASEB J., 2, A1151, 1988 January, 1988
93. Receptor-specific interactions of the nigro-striatal dopamine projections with striatal neurotensin systems in the rat brain Merchant, K. M., L. Bush, J. W. Gibb and G. R. Hanson Abst. Soc. Neurosci., 14:114 January, 1988
94. Tonic dopaminergic regulation of discrete neurotensin systems Merchant, K.M., J.W. Gibb and G.R. Hanson FASEB J., 3, A729, 1988. January, 1988
95. Differential responses of extrapyramidal peptides to fenfluramine, norfenfluramine and methamphetamine Singh, N.A., K.M. Merchant, J.W. Gibb and G.R. Hanson FASEB J., 3, A729, 1988 January, 1988
96. Does the nigral-striatal dopamine pathway mediate the effects of methamphetamine and haloperidol on neurotensin systems? Merchant, K. M., L. Bush, J. W. Gibb and G. R. Hanson FASEB J., 2, A1151, 1988 January, 1988
97. Effects of methamphetamine on mesolimbic neurotensin systems of the rat brain Merchant, K.M., A. A. Letter, J. W. Gibb and G. R. Hanson Abst. Soc. Neurosci., 13:1273,1987 January, 1987
98. Effects of dopamine antagonists on methamphetamine-induced changes in CNS neurotensin systems Letter, A.A., K.M. Merchant, J.W. Gibb and G.R. Hanson Fed. Proc., 45: 917, 1986 January, 1986
99. Multiple toxic doses of methamphetamine alter neurotensin concentrations in various regions of the rat brain Hanson, G. R., K.M. Merchant, J. W. Gibb and A. A. Letter Fed. Proc., 45: 793 January, 1986
100. Responses of brain neurotensin-like immunoreactivity to 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine(MDA) Merchant, K.M., A. A. Letter, D. M. Stone, J. W. Gibb and G. R. Hanson Fed. Proc., 45: 1060, 1986 January, 1986
101. Roles of D2 and 5HT2 receptors in mediating the effects of methamphetamine, 3,4-methylenedioxy-amphetamine and 3,4-methylenedioxymethamphetamine on striatonigral neurotensin systems Letter, A.A., K.M. Merchant, J.W. Gibb and G.R. Hanson Abst. Soc. Neurosci., 12:1005, 1986 January, 1986
102. Comparison of responses by substance P and substance K systems to methamphetamine treatments Hanson, G. R., A. A. Letter, K.M. Merchant and J. W. Gibb Abst. Soc. Neurosci., 12:1007, 1986 January, 1986
103. Effects of MDA and MDMA on neurotensin and substance P systems in rat basal ganglia NIDA Research Monograph series 76, Committee on Problems of Drug Dependence Hanson, G. R., K.M. Merchant, A. A. Letter, D. M. Stone and J. W. Gibb Proceedings of the 48th Annual Scientific Meeting, pp.316, 1986. January, 1986



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Improving Clinical Success Through Optimal Target Identification and Validation 8thANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE:An Intensive Course on Translating Research into Drugs February, 2014
II. Embarking on a Drug Discovery Campaign 8thANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE:An Intensive Course on Translating Research into Drugs February, 2014
Improving Clinical Success Through Optimal Target Validation 7thANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE: An Intensive Course on Translating Research into Drugs February, 2013
Is there an opportunity to refine disease taxonomy based on biomarkers for brain disorders? Biomarkers for Brain Disorders: Challenges and Opportunities February, 2013

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.